OBI — Ondine Biomedical Share Price
Last trade - 00:00- £56.64m
- £51.45m
- CA$2.05m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 15.24 | ||
| Price to Tang. Book | 15.24 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 51.14 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -282.74% | ||
| Return on Equity | -426.2% | ||
| Operating Margin | -948.95% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | 0.45 | 2.57 | 0.64 | 1.2 | 2.05 | n/a | n/a | 28.65% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Ondine Biomedical Inc. is a Canadian life sciences company. The Company specializes in light-activated antimicrobial therapies (photo disinfection) for the prevention and treatment of infections, including those caused by multidrug-resistant organisms. The Company has a pipeline of investigational products, based on its proprietary photo disinfection technology, in various stages of development. The Company's nasal photo disinfection system has a CE mark in Europe and is approved in Canada, Australia, Mexico and several other countries under the name Steriwave. In the United States, it has been granted Qualified Infectious Disease Product designation and Fast Track status by the FDA and is undergoing clinical trials for regulatory approval. Its products beyond nasal photo disinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, serious burns, chronic wounds, central line bloodstream infections and other indications.
Directors
- Jean Charest CHM
- Nicolas Loebel PRE
- Carolyn Cross CEO
- Cameron Lawrence CFO (40)
- Thomas Dawson VOP
- Merrill Biel DRC
- Junaid Bajwa NED
- Mike Farrar NED
- Simon Sinclair NED
- Craig Tooman NED (55)
- Michael Crane IND
- Margaret Shaw IND (57)
- Colin Watt IND
- Jean Duvall NID
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- September 9th, 1996
- Public Since
- December 6th, 2021
- No. of Employees
- 43
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- London Stock Exchange
- Shares in Issue
- 444,233,631
- Address
- 888-1100 Melville St, VANCOUVER, V6E 4A6
- Web
- https://ondinebio.com/
- Phone
- +1 6046690555
- Auditors
- PricewaterhouseCoopers LLP
Latest News for OBI
Upcoming Events for OBI
Similar to OBI
Abingdon Health
London Stock Exchange
Advanced Medical Solutions
London Stock Exchange
Angle
London Stock Exchange
Aoti
London Stock Exchange
Aptamer
London Stock Exchange
FAQ
As of Today at 22:26 UTC, shares in Ondine Biomedical are trading at 12.75p. This share price information is delayed by 15 minutes.
Shares in Ondine Biomedical last closed at 12.75p and the price had moved by +61.9% over the past 365 days. In terms of relative price strength the Ondine Biomedical share price has outperformed the FTSE All Share Index by +46.36% over the past year.
There is no consensus recommendation for this security.
Find out moreOndine Biomedical does not currently pay a dividend.
Ondine Biomedical does not currently pay a dividend.
Ondine Biomedical does not currently pay a dividend.
To buy shares in Ondine Biomedical you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 12.75p, shares in Ondine Biomedical had a market capitalisation of £56.64m.
Here are the trading details for Ondine Biomedical:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: OBI
Based on an overall assessment of its quality, value and momentum Ondine Biomedical is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Ondine Biomedical. Over the past six months, its share price has underperformed the FTSE All Share Index by -7.7%.
As of the last closing price of 12.75p, shares in Ondine Biomedical were trading +23.22% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Ondine Biomedical PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at 12.75p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Ondine Biomedical's management team is headed by:
- Jean Charest - CHM
- Nicolas Loebel - PRE
- Carolyn Cross - CEO
- Cameron Lawrence - CFO
- Thomas Dawson - VOP
- Merrill Biel - DRC
- Junaid Bajwa - NED
- Mike Farrar - NED
- Simon Sinclair - NED
- Craig Tooman - NED
- Michael Crane - IND
- Margaret Shaw - IND
- Colin Watt - IND
- Jean Duvall - NID